Stockscreener 앱 받기
15.61
0.36%
-0.26
전일 마감가:
$15.87
열려 있는:
$15.87
하루 거래량:
18,491
Relative Volume:
0.06
시가총액:
$803.07M
수익:
-
순이익/손실:
$-69.13M
주가수익비율:
-13.01
EPS:
-1.2
순현금흐름:
$-50.91M
1주 성능:
-3.22%
1개월 성능:
-44.26%
6개월 성능:
-14.29%
1년 성능:
+42.98%
1일 변동 폭
$15.58
$16.09
1주일 범위
$15.04
$16.51
52주 변동 폭
$10.60
$29.60
Tyra Biosciences Inc Stock (TYRA) Company Profile
명칭
Tyra Biosciences Inc
전화
(619) 728-4760
주소
2656 STATE STREET, CARLSBAD
TYRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| TYRA | 15.74 | 803.07M | 0 | -69.13M | -50.91M | -1.20 |
| VRTX | 446.48 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.49 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.15 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.56 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-06-30 | 개시 | Wedbush | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-06-23 | 개시 | H.C. Wainwright | Buy |
| 2022-03-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-10-11 | 개시 | BofA Securities | Buy |
| 2021-10-11 | 개시 | Cowen | Outperform |
| 2021-10-11 | 개시 | Jefferies | Buy |
모두보기
Tyra Biosciences Inc 주식(TYRA)의 최신 뉴스
How to Take Advantage of moves in (TYRA) - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 5%Here's Why - MarketBeat
Short Interest in Tyra Biosciences, Inc. (NASDAQ:TYRA) Drops By 20.0% - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Shares Gap UpWhat's Next? - MarketBeat
RA Capital Management, L.P. Increases Stake in Tyra Biosciences Inc - GuruFocus.com
Tyra Biosciences to Present FGFR Precision Medicine Updates at Major Healthcare Conferences | TYRA Stock News - StockTitan
Equities Analysts Offer Predictions for TYRA FY2024 Earnings - MarketBeat
FMR LLC Increases Stake in Tyra Biosciences Inc - GuruFocus.com
Tyra Biosciences stock target cut, retains buy rating on clinical data - Investing.com Canada
HC Wainwright Has Lowered Expectations for Tyra Biosciences (NASDAQ:TYRA) Stock Price - MarketBeat
Tyra Biosciences director Nina Kjellson sells $1.28 million in stock By Investing.com - Investing.com Australia
Tyra Biosciences’ Q3 2024: Clinical Progress and Financial Resilience - TipRanks
Tyra Biosciences director Nina Kjellson sells $1.28 million in stock - Investing.com
Tyra Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - PR Newswire
Tyra Biosciences director Nina S. Kjellson sells shares worth $194k - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by Auour Investments LLC - MarketBeat
Long Term Trading Analysis for (TYRA) - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up After Insider Buying Activity - MarketBeat
Tyra Biosciences director Nina Kjellson sells $2.28m in stock By Investing.com - Investing.com Australia
Tyra Biosciences director Nina Kjellson sells $2.28m in stock - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) CFO Purchases $152,000.00 in Stock - MarketBeat
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock By Investing.com - Investing.com South Africa
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock - Investing.com
Tyra Biosciences (NASDAQ:TYRA) Trading Down 10.2%Here's What Happened - MarketBeat
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment By Investing.com - Investing.com Australia
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment - Investing.com
Piper Sandler maintains Overweight on Tyra Biosciences stock By Investing.com - Investing.com Canada
Tyra Biosciences stock target lifted, retains buy on clinical trial data - Investing.com Canada
Tyra Biosciences (NASDAQ:TYRA) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
FDA clears Tyra Biosciences' trial for dwarfism drug By Investing.com - Investing.com Australia
Tyra Biosciences (NASDAQ:TYRA) Price Target Raised to $32.00 at HC Wainwright - MarketBeat
FDA clears Tyra Biosciences' trial for dwarfism drug - Investing.com India
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) - PR Newswire
Tyra Biosciences (NASDAQ:TYRA) Shares Gap DownWhat's Next? - MarketBeat
Tyra Biosciences' (TYRA) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? - Benzinga
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer - Marketscreener.com
(TYRA) Long Term Investment Analysis - Stock Traders Daily
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) - PR Newswire
Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet - MSN
Tyra Biosciences (NASDAQ:TYRA) Sets New 52-Week HighWhat's Next? - MarketBeat
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - Marketscreener.com
Tyra Biosciences stock soars to 52-week high of $28.86 - Investing.com India
Tyra Biosciences stock soars to 52-week high of $28.86 By Investing.com - Investing.com South Africa
RA Capital Management, L.P. Reduces Stake in Tyra Biosciences Inc - Yahoo Finance
Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 19,084 Shares of Stock - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Shares Up 4.2%Here's Why - MarketBeat
Tyra Biosciences Inc (TYRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
0.16%
자본화:
|
볼륨(24시간):